市場調查報告書
商品編碼
1606542
全球醫療生物感測器市場 - 2024-2031Global Medical biosensors market - 2024-2031 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
概述
2023年,全球醫療生物感測器市場規模達到56.5億美元,預計2031年將達到109億美元,2024-2031年預測期間複合年成長率為8.5%。
生物感測器是一種分析設備,它結合了感測器系統和感測器等生物檢測元件,將生物響應轉換為電訊號。它的工作原理是與被測分析物通訊,並透過感測器將響應轉換為電訊號。醫用生物感測器在醫療診斷和患者監測中發揮重要作用,因為它們利用生物分子、組織和生物體,特別適合應對即時檢測挑戰。葡萄糖生物感測器廣泛應用於糖尿病診斷的臨床應用,佔全球市場的85%。生物感測器領域已擴展到多種類型,包括免疫感測器和熱生物感測器。
科技進步的崛起
技術進步透過提高這些設備的精度、功能和可訪問性來推動全球醫療生物感測器市場的成長。奈米技術創新提高了生物感測器的靈敏度和特異性,從而實現了早期疾病診斷。人工智慧和機器學習演算法已將生物感測器轉變為智慧診斷工具,提供即時資料分析、預測見解和個人化健康建議。
靈活的穿戴式生物感測器已將其應用擴展到臨床環境之外,從而實現持續的健康監測和遠端患者護理。藍牙和 NFC 等無線通訊技術實現了生物感測器和數位健康平台之間的無縫連接。微型化和生物相容性材料使生物感測器更加方便用戶使用,使其成為現代醫療系統中不可或缺的工具。
例如,2024 年 10 月,義法半導體推出了一款新型醫療生物感測晶片 ST1VAFE3BX,適用於智慧手錶、運動手環、互聯戒指和智慧眼鏡等醫療保健穿戴式裝置。該晶片採用高精度生物電位輸入和慣性感測,確保更快的性能和更低的功耗。 。來自 vAFE 的類比訊號與來自加速度感測器的運動資料組合在一個緊湊的封裝中,可以進行精確的上下文感知資料分析,直接在感測器上支援人工智慧演算法。
準確性和可靠性限制
儘管生物感測器取得了顯著進步,但在不同條件下保持準確性和可靠性的能力始終是一個挑戰。這種變化包括環境條件、用戶變化和感測器退化。所有這些因素都會影響設備的性能,導致讀數誤導。在醫療保健應用的關鍵領域,例如糖尿病管理中的血糖監測,輕微的不準確甚至可能是致命的。如此高品質的性能和可靠性通常需要先進的技術和頻繁的校準,這會增加成本和維護要求。因此,許多應用限制了生物感測器在當前市場中的準確性和可靠性的可用性。
Overview
The global medical biosensors market reached US$ 5.65 billion in 2023 and is expected to reach US$ 10.90 billion by 2031, growing at a CAGR of 8.5% during the forecast period 2024-2031.
A biosensor is an analytical device that combines biological detecting elements like a sensor system and a transducer to convert a biological response into an electrical signal. It works by communicating with the analyte being tested and converting the response into an electrical signal by the transducer. Medical biosensors play a significant role in medical diagnostics and patient monitoring, as they are uniquely suited to real-time detection challenges due to their use of biological molecules, tissues, and organisms. Glucose biosensors are widely used in clinical applications for diabetes diagnosis, accounting for 85% of the world market. The biosensor field has expanded into various types, including immunosensors and thermal biosensors.Market Dynamics: Drivers & Restraints
Rise in the Technological Advancements
Technological advancements are driving the growth of the global medical biosensors market by improving the precision, functionality, and accessibility of these devices. Nanotechnology innovations have enhanced the sensitivity and specificity of biosensors, enabling early disease diagnosis. Artificial intelligence and machine learning algorithms have transformed biosensors into smart diagnostic tools, providing real-time data analysis, predictive insights, and personalized health recommendations.
Flexible and wearable biosensors have expanded their applications beyond clinical settings, enabling continuous health monitoring and remote patient care. Wireless communication technologies like Bluetooth and NFC have enabled seamless connectivity between biosensors and digital health platforms. Miniaturization and biocompatible materials have made biosensors more user-friendly, making them indispensable tools in modern healthcare systems.
For instance, in October 2024, STMicroelectronics has introduced a new medical bio-sensing chip, the ST1VAFE3BX, for healthcare wearables like smart watches, sports bands, connected rings, and smart glasses. The chip uses high-accuracy biopotential input and inertial sensing, ensuring faster performance with lower power consumption.ST's biosensor has enabled the development of precise athlete performance monitoring systems, including ECG analysis in chest bands or small patches. The combination of analog signal from the vAFE with motion data from the acceleration sensor in a compact package allows for precise and context-aware data analysis, supporting AI algorithms directly on the sensor.
Accuracy and Reliability Limitations
Although biosensors have advanced significantly, the ability to maintain accuracy and reliability under varying conditions has always been a challenge. Such variation includes environmental conditions, user variability, and sensor deterioration. All these factors affect the performance of the device and thus lead to misleading readings. In critical areas of healthcare applications, such as glucose monitoring in diabetic management, slight inaccuracies can even be fatal. Such high-quality performance and dependability usually require advanced technology and frequent calibrations, which increase costs and maintenance requirements. With these, many applications restrict the usability of biosensors for accuracy and reliability in the ongoing market.
The global medical biosensors market is segmented based on product type, application, technology, end user and region.
Wearable Biosensors segment is expected to dominate the medical biosensors market share
The wearable biosensors segment holds a major portion of the medical biosensors market share and is expected to continue to hold a significant portion of the medical biosensors market share during the forecast period.
Wearable biosensors are revolutionizing the medical biosensors market by providing real-time health monitoring and diagnostic capabilities in a non-invasive manner. These devices, such as smartwatches, patches, and fitness bands, measure biomarkers like glucose levels, heart rate, blood pressure, and oxygen saturation. The rise in chronic diseases and demand for personalized medicine has driven the adoption of wearable biosensors. They are also used in remote patient monitoring, telehealth applications, and fitness tracking, especially during the COVID-19 pandemic. Advancements in sensor miniaturization, wireless connectivity, and AI-driven platforms are expected to further enhance the adoption and functionality of wearable biosensors, expanding their role in modern healthcare.
For instance, in June 2024, Trinity Biotech, a biotechnology company specializing in human diagnostics and diabetes management solutions, has launched its continuous glucose monitoring (CGM) microsite. The site will provide stakeholders with insights into the company's vision for the next generation of its CGM biosensor technology and AI-driven health analytics platform, as well as international commercialization of these solutions.
Diagnostics segment is the fastest-growing segment in medical biosensors market share
The diagnostics segment is the fastest-growing segment in the medical biosensors market share and is expected to hold the market share over the forecast period.
Diagnostics are a crucial segment of the global medical biosensors market, utilizing biosensor technology for accurate, rapid, and sensitive disease detection. These sensors are increasingly used in point-of-care diagnostics for conditions like diabetes, infectious diseases, cancer, and cardiovascular ailments, offering convenience and speed over traditional laboratory methods. They detect specific biological markers through electrochemical, optical, and piezoelectric methods, ensuring high precision and reliability. Advancements in portable and miniaturized biosensors have extended their use into home diagnostics, empowering individuals to self-monitor their health and reducing healthcare facility burden. The growing focus on personalized and preventive medicine and increasing incidence of chronic and infectious diseases highlight the importance of diagnostics in the biosensors market.
North America is expected to hold a significant position in the medical biosensors market share
North America holds a substantial position in the medical biosensors market and is expected to hold most of the market share due to well-established healthcare infrastructure, advanced technological capabilities, and willingness to adopt innovative medical devices. In the U.S., chronic diseases have a higher prevalence, creating enormous opportunities for biosensors in hospitals or home care. Moreover, investments in healthcare research and reimbursement policies promote the exceptional adoption of biosensors for diagnosis and monitoring. Further, the contributions of Canada towards North America's market growth are significant; it is rapidly adopting wearable biosensors in its elderly population.
For instance, in November 2024, A new variant of human mpox has claimed the lives of 5% of people with reported infections in the Democratic Republic of the Congo since 2023, many of them children. The outbreak has spread to several other countries, leading to the World Health Organization declaring it a Public Health Emergency of International Concern. A different, rarely fatal mpox variant has caused an outbreak in over 100 countries since 2022. Researchers from the University of California School of Medicine and Boston University have developed an optical biosensor that can rapidly detect monkeypox, the virus that causes mpox, allowing clinicians to diagnose the disease at the point of care.
Moreover, in November 2023, A Malmo University researcher has developed a wireless biosensor that allows early detection of infections through smart catheters, diapers, or wound dressings. The technology has potential applications in health monitoring and disease monitoring. However, it requires reliable, user-friendly sensors that don't require traditional integrated circuits or bulky batteries.
Europe is growing at the fastest pace in the medical biosensors market
Europe holds the fastest pace in the medical biosensors market and is expected to hold most of the market share due to its robust healthcare infrastructure, increasing prevalence of chronic diseases, and strong government support for innovative medical technologies. The aging population in Europe is driving demand for advanced diagnostic and monitoring devices, particularly wearable devices, for real-time health monitoring. The region's emphasis on personalized and preventive healthcare has accelerated the adoption of biosensors, particularly wearable devices. Europe is also investing in research and development, supported by regulatory frameworks and initiatives like the European Union's Horizon programs. The COVID-19 pandemic has further boosted demand for biosensors in home diagnostics and point-of-care applications. Technological advancements, including nanotechnology and AI, and IoT-enabled medical devices are also driving the market.
For instance, in October 2024, Bruker Corporation has acquired Dynamic Biosensors GmbH, a Munich-based biosensor development company, strengthening its biophysical portfolio for molecular interaction and kinetic analysis. Dynamic Biosensors offers deep insights into inter-molecular and molecule-single cell interactions, supporting drug discovery in pharma, biotech, and basic research.
The major global players in the medical biosensors market include Abbott Laboratories, Bio-Rad Laboratories Inc, Biosensors International Group, Ltd, DuPont Biosensor Materials, Ercon, Inc, Johnson & Johnson, Koninklijke Philips N.V, LifeScan, Inc Medtronic, Molex LLC among others.
Emerging Players
The emerging players in the medical biosensors market include Biolinq, Nemaura Medical, GlySens Incorporated and among others
The global medical biosensors market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.